Ecabet

Ecabet

SCHEMBL17747954

CC(C)c1cc2c(cc1S(=O)(=O)O)[C@@]1(C)CCC[C@@](C)(C(=O)O)[C@@H]1CC2.O.[NaH]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Ecabet. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
OPRK1 known ✓ P41145 1/20 0.96
MMP8 known ✓ P22894 9/20 0.62
PDE4D known ✓ Q08499 1/20 0.54
NR1I2 O75469 1/20 0.96
MMP3 P08254 9/20 0.62
MMP9 P14780 8/20 0.62
KARS1 Q15046 2/20 0.60
RXRA P19793 1/20 0.60
CCNE1 P24864 1/20 0.60
CDK2 P24941 1/20 0.60
RXRB P28702 1/20 0.60
RXRG P48443 1/20 0.60
POLA1 P09884 4/20 0.54
POLB P06746 1/20 0.54
APEX1 P27695 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ecabet SCHEMBL437091 0.99 NR1I2 (0.98) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL10935978 0.99 NR1I2 (0.98) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL10937322 0.99 NR1I2 (0.98) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL7615516 0.99 NR1I2 (0.98) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL10938694 0.99 NR1I2 (0.98) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL10937325 0.99 NR1I2 (0.98) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL29727401 0.98 NR1I2 (1.00) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL373030 0.98 NR1I2 (1.00) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL8614405 0.98 NR1I2 (1.00) NR1I2OPRK1MMP3MMP8MMP9
Ecabet SCHEMBL6546246 0.98 NR1I2 (1.00) NR1I2OPRK1MMP3MMP8MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024237610-A1 COLONIC PURGATIVE TABLET AND COLONIC PURGATIVE COMPRISING SAME 주식회사 한국팜비오 2024-11-21 WO claimed
US-12582606-B2 Tablet and method for producing tablet SUNSHO PHARMACEUTICAL CO., LTD. (JP) 2026-03-24 US disclosed
US-20220218616-A1 TABLET AND METHOD FOR PRODUCING TABLET SUNSHO PHARMACEUTICAL CO., LTD. (JP) 2022-07-14 US disclosed
WO-2020138402-A1 ANTIVIRAL AGENT FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE AND USE THEREOF クリニジェン株式会社 2020-07-02 WO disclosed
EP-3023109-A1 ORALLY DISINTEGRATING TABLET Sanwa Kagaku Kenkyusho Co., Ltd (JP) 2016-05-25 EP disclosed
US-20160136091-A1 Orally Disintegrating Tablet SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2016-05-19 US disclosed
CN-105377303-A Orally disintegrating tablet SANWA KAGAKU KENKYUSHO CO 2016-03-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12582606-B2 Tablet and method for producing tablet GRHPR, RCC1, KIT OPRK1 3933/4885MMP8 1499/4885PDE4D 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.